Home » Topics » Regulatory » NMPA

NMPA
RSS

CFDA clears HG-146 to enter clinical trials for multiple myeloma

May 11, 2018

CFDA approves IND for Suzhou Alphamab's HER2 bispecific antibody KN-026

April 16, 2018

Chinese authorities approve clinical trials of ZKAB-001

Jan. 30, 2018

China FDA accepts IND for Ascentage's IAP inhibitor

Jan. 9, 2018

CFDA designates lenvatinib for priority review and approval for HCC

Dec. 28, 2017

Clover Biopharmaceuticals receives approval to initiate clinical trials of SCB-808 in China

Dec. 28, 2017

Ebola vaccine approved in China

Oct. 26, 2017

Fosun Pharma reports Chinese IND application for FCN-437c

July 19, 2017

CStone cleared to begin clinical trials of CS-1001 in China

July 18, 2017

China FDA accepts fruquintinib NDA for advanced colorectal cancer

June 12, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.